They could do something like this, Contingent Valu
Post# of 148178
(Total Views: 341)
Posted On: 12/10/2019 7:16:15 AM
Re: Cytodynamite #12347
They could do something like this, Contingent Value Rights (CVRs) that was offered Tobira, up to 1.7B depending on completion of certain milestones for them. It had a 100M market cap when this deal was announced.
So milestones for mono approval, tnbc approval, other cancer approval, nash approval, etc....
https://drug-dev.com/allergan-to-acquire-tobi...n-in-nash/
Allergan plc recently announced it has entered into a definitive agreement under which Allergan will acquire Tobira for an upfront payment of $28.35 per share, in cash, and up to $49.84 per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory, and commercial milestones, for a total potential consideration of up to $1.695 billion . The Boards of Directors of both companies have unanimously approved the transaction.
NASH is a severe type of non-alcoholic fatty liver disease (NAFLD), which is characterized by the accumulation of fat in the liver with no other apparent causes. NASH occurs when the accumulation of liver fat is accompanied by inflammation and cellular damage. The inflammation can lead to fibrosis (scarring) of the liver and eventually progress to cirrhosis, portal hypertension, liver cancer, and eventual liver failure.
The acquisition adds Cenicriviroc (CVC) and Evogliptin, two differentiated, complementary development programs for the treatment of the multi-factorial elements of NASH, including inflammation, metabolic syndromes, and fibrosis, to Allergan’s global Gastroenterology R&D pipeline.
“The acquisition of Tobira is a strategic R&D investment within a white space area of our global Gastroenterology franchise and an opportunity to advance the development of novel treatments for NASH,” said Brent Saunders, CEO and President of Allergan. “With the increasing rates of diabetes, obesity, and other metabolic conditions in the US and in developed nations globally, NASH is set to become one of the next epidemic-level chronic diseases we face as a society. It is important that we invest in new treatments today so that healthcare systems, providers and patients have treatment options to face this challenge in the coming years.”
“With this acquisition, Allergan will now have one of the strongest portfolios of development-stage programs for the treatment of NASH, with Cenicriviroc as the cornerstone. We will continue to look for differentiated development-stage assets that can bolster this position and enhance our commitment to innovation in this disease,” added Saunders.
Cenicriviroc (CVC) is a first-in-class, once-daily, oral Phase III ready potent im
So milestones for mono approval, tnbc approval, other cancer approval, nash approval, etc....
https://drug-dev.com/allergan-to-acquire-tobi...n-in-nash/
Allergan plc recently announced it has entered into a definitive agreement under which Allergan will acquire Tobira for an upfront payment of $28.35 per share, in cash, and up to $49.84 per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory, and commercial milestones, for a total potential consideration of up to $1.695 billion . The Boards of Directors of both companies have unanimously approved the transaction.
NASH is a severe type of non-alcoholic fatty liver disease (NAFLD), which is characterized by the accumulation of fat in the liver with no other apparent causes. NASH occurs when the accumulation of liver fat is accompanied by inflammation and cellular damage. The inflammation can lead to fibrosis (scarring) of the liver and eventually progress to cirrhosis, portal hypertension, liver cancer, and eventual liver failure.
The acquisition adds Cenicriviroc (CVC) and Evogliptin, two differentiated, complementary development programs for the treatment of the multi-factorial elements of NASH, including inflammation, metabolic syndromes, and fibrosis, to Allergan’s global Gastroenterology R&D pipeline.
“The acquisition of Tobira is a strategic R&D investment within a white space area of our global Gastroenterology franchise and an opportunity to advance the development of novel treatments for NASH,” said Brent Saunders, CEO and President of Allergan. “With the increasing rates of diabetes, obesity, and other metabolic conditions in the US and in developed nations globally, NASH is set to become one of the next epidemic-level chronic diseases we face as a society. It is important that we invest in new treatments today so that healthcare systems, providers and patients have treatment options to face this challenge in the coming years.”
“With this acquisition, Allergan will now have one of the strongest portfolios of development-stage programs for the treatment of NASH, with Cenicriviroc as the cornerstone. We will continue to look for differentiated development-stage assets that can bolster this position and enhance our commitment to innovation in this disease,” added Saunders.
Cenicriviroc (CVC) is a first-in-class, once-daily, oral Phase III ready potent im
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼